Belviq safely and effectively see full prescribing information for belviq belviq (lorcaserin hydrochloride) tablets, for oral use initial us approval: 2012 indications and usage belviq is a serotonin 2c receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight. Belviq package insert. M odest weight loss of 5% to 10% among patients who are overweight or obese can result in a clinically relevant reduction in cardiovascular (cv) disease risk 1 this amount of weight loss can increase insulin sensitivity in adipose tissue, liver, and muscle, and have a positive impact on blood sugar, blood pressure, triglycerides, and high-density lipoprotein cholesterol 1,2.
belviq package insert
Important safety information qsymia is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (maois); or in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in qsymia. Contact us. if you have any questions about qsymia, please contact vivus medical information at the number below. medical information phone: 1 (888) 998-4887. The titration schedule for the studies was faster than what is recommended in the qsymia package insert. subjects took the 3.75 mg/23 mg strength for one week, then the 7.5 mg/46 mg strength for one week (unless randomized to this arm); then the 11.25 mg/69 mg strength for one week, followed by the 15 mg/92 mg strength. 1,2.
